Proteasome Inhibitors Market Comprehensive Insight by Growth Rate, Industry Status, Forecast till 2027

The global proteasome inhibitors market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Proteasomes are protein complexes that degrade unneeded or damaged proteins by proteolysis. Additionally, enzymes that support such reactions are known as proteases. Furthermore, the proteasome is a cylindrical complex that contains a core of four stacked rings which forms a central pore. The major factor driving the growth of the market is the rising prevalence of lymphoma across the globe.

According to the Leukemia & Lymphoma Society, one person is diagnosed with lymphoma approximately every 3 minutes in the US. Additionally, in 2021, an estimated combined total of 186,400 people are anticipated to be diagnosed with leukemia, lymphoma or myeloma in the US. Furthermore, in 2021, new cases of leukemia, lymphoma and myeloma are anticipated to account for 9.8% of the estimated 1,898,160 new cancer cases. Moreover, an estimated 1,519,907 people are living with or in remission from leukemia, lymphoma, myeloma in the US. Hence, the increasing prevalence of lymphoma is driving the demand for proteasome inhibitors as they mediate cell cycle arrest and apoptosis causing dysregulation of several proapoptotic proteins.

To Request a Sample of our Report on Proteasome Inhibitors Market: https://www.omrglobal.com/request-sample/proteasome-inhibitors-market

Some major players in the market include Johnson and Johnson Services, Inc., Amgen, Inc., and Celgene Corp., among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in February 2021, Oncopeptides AB announced that it has received approval for melphalan flufenamide from the US FDA. It is used in combination with dexamethasone for adult patients with relapsed or refractory multiple myeloma.

Market Coverage

• The market number available for - 2020-2027

• Base year- 2020

• Forecast period- 2021-2027

Segment Covered-

• By Drugs

• By Application

• By Distribution Channel

• By End-Users

Regions Covered-

• North America

• Europe

• Asia-Pacific

• Rest of the World

Competitive Landscape- Johnson and Johnson Services, Inc., Amgen, Inc., and Celgene Corp., among others.

(Get 15% Discount on Buying this Report)

A full Report of Proteasome Inhibitors Market is Available @ https://www.omrglobal.com/industry-reports/proteasome-inhibitors-market

Global Proteasome Inhibitors Market Report by Segment

By Drugs

• Bortezomib

• Carfilzomib

• Ixazomib

By Application

• Lymphoma

• Mantle Cell Lymphoma

• Multiple Myeloma

By Distribution Channel

• Hospital Pharmacy

• Online Pharmacy

• Retail Pharmacy

Global Proteasome Inhibitors Market Report by Region

North America

· United States

· Canada

Europe

· UK

· Germany

· Spain

· France

· Italy

· Rest of Europe

Asia-Pacific

· India

· China

· Japan

· South Korea

· Rest of APAC

Rest of the World

· Latin America

· Middle East & Africa

Reasons to buy from us -

1. We cover more than 15 major industries, further segmented into more than 90 sectors.

2. More than 120 countries are for analysis.

3. Over 100+ paid data sources mined for investigation.

4. Our expert research analysts answer all your questions before and after purchasing your report.

Media Contact:

Company Name: Orion Market Research

Contact Person: Mr. Anurag Tiwari

Email: info@omrglobal.com

Contact no: +91 7803040404

About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

This release was published on openPR.